Dyne Therapeutics Competitors
| DYN Stock | USD 17.80 0.24 1.37% |
Pair Correlation for Dyne Therapeutics and CG Oncology Details
Very strong inverse diversification
Across the chosen horizon, Dyne Therapeutics and CG Oncology show a correlation of -0.51 and fall into the Very strong inverse diversification bucket. The overlap area shows the portion of risk that can be diversified away by holding both instruments together.
Moving together with Dyne Stock
Moving against Dyne Stock
Experienced market participants anticipate that Dyne Therapeutics' price will even out over time. Periods when Dyne Therapeutics' deviates significantly from its historical mean may warrant further fundamental analysis.
Dyne Therapeutics Competition Correlation Matrix
Competition correlation for Dyne Therapeutics matters because related securities often respond to the same industry, factor, or macro drivers even when their business stories differ. The useful question is whether competitors are behaving like true alternatives or simply tracking the same sector move with different volatility.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Dyne Stock performing well and Dyne Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dyne Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RARE | 3.17 | -0.53 | 0.00 | -0.51 | 0.00 | 6.75 | 46.05 | |||
| SLNO | 2.44 | -0.49 | 0.00 | -0.62 | 0.00 | 3.92 | 17.86 | |||
| CNTA | 1.91 | 0.12 | 0.07 | 0.16 | 2.22 | 4.04 | 11.95 | |||
| XENE | 2.58 | 0.59 | 0.27 | 0.57 | 1.88 | 3.78 | 54.25 | |||
| APGE | 2.11 | -0.16 | 0.00 | -0.60 | 0.00 | 4.97 | 16.66 | |||
| AAPG | 2.73 | -0.42 | 0.00 | -0.67 | 0.00 | 4.97 | 17.03 | |||
| MIRM | 2.25 | 0.64 | 0.15 | 0.51 | 3.50 | 5.97 | 25.74 | |||
| CELC | 2.00 | 0.15 | 0.07 | 0.13 | 2.59 | 3.60 | 17.89 | |||
| TLX | 2.89 | 0.15 | 0.06 | 0.14 | 3.35 | 5.72 | 24.23 | |||
| CGON | 2.79 | 0.93 | 0.34 | 0.84 | 2.31 | 4.83 | 35.37 |
Peer Comparison: Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Dyne Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dyne Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Compare Dyne Therapeutics and related stocks such as Ultragenyx, Soleno Therapeutics, and Centessa Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE | -6.8 M | -6.8 M | -16.3 M | -35.1 M | -59.8 M | -145.6 M | -245.9 M | -302.1 M | -197.6 M | -402.7 M | -186.6 M | -454 M | -707.4 M | -606.6 M | -569.2 M | -575 M | -546.2 M |
| SLNO | -6.5 M | -6.5 M | -6.5 M | -3.7 M | -13.9 M | -15.9 M | -12.1 M | -15.7 M | -13.3 M | -30.8 M | -24.6 M | -30.9 M | -24.1 M | -39 M | -175.8 M | 20.9 M | 21.9 M |
| CNTA | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -5.3 M | -10.7 M | -381.9 M | -216.2 M | -151.1 M | -235.8 M | -212.2 M | -222.8 M |
| XENE | -12 M | -12 M | -4.3 M | 12 M | 13 M | -15.8 M | -23 M | -30.7 M | -34.5 M | -41.6 M | -28.8 M | -78.9 M | -125.4 M | -182.4 M | -234.3 M | -345.9 M | -328.6 M |
| APGE | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -39.8 M | -84 M | -182.1 M | -255.8 M | -243.1 M |
| AAPG | -107.8 M | -107.8 M | -107.8 M | -107.8 M | -107.8 M | -107.8 M | -107.8 M | -118.5 M | -345.3 M | -1.5 B | -677.6 M | -782.4 M | -882.9 M | -925.6 M | -405.4 M | -364.9 M | -383.1 M |
| MIRM | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -17.3 M | -52.6 M | -103.3 M | -84 M | -135.7 M | -163.4 M | -87.9 M | -23.4 M | -24.5 M |
| CELC | -2.3 M | -2.3 M | -2.3 M | -2.3 M | -2.3 M | -2.3 M | -3.3 M | -6.3 M | -7.5 M | -7.4 M | -9.5 M | -29.6 M | -40.4 M | -63.8 M | -111.8 M | -100.6 M | -95.6 M |
| TLX | -289 K | -2.5 M | -2.5 M | -2.5 M | 5.4 M | -132 K | -44 K | -6.4 M | -13.8 M | -27.9 M | -44.9 M | -80.5 M | -104.1 M | 5.2 M | 49.9 M | -10.7 M | -11.2 M |
| CGON | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -12.8 M | -35.4 M | -48.6 M | -88 M | -161 M | -152.9 M |
Dyne Therapeutics Competitive Analysis
Within its peer group that includes Ultragenyx, Soleno Therapeutics, and Centessa Pharmaceuticals, Dyne Therapeutics stands out in several ways. The company commands a 2.90 B market valuation. Dyne Therapeutics posts a -55.71% return on equity, reflecting current earnings headwinds. Return on equity favors Dyne Therapeutics at -55.71%, well ahead of Ultragenyx at -608.47%. Market capitalization diverges sharply here: 2.90 B versus 1.78 B, giving Dyne Therapeutics a clear size advantage. Market capitalization diverges sharply here: 3.95 B versus 2.90 B, giving Centessa Pharmaceuticals a clear size advantage.| Better Than Average | Worse Than Peers | View Performance Chart |
Dyne Therapeutics Competition Peer Performance Charts
How to Analyze Dyne Therapeutics Against Peers
Dyne Therapeutics' peer analysis compares Dyne Therapeutics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Dyne Therapeutics trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Dyne Therapeutics leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
Dyne Therapeutics' return on invested capital tops the peer average, meaning each dollar of capital is working harder here. Momentum scores across the peer set show which names are gaining relative strength and which are fading. Relative comparison helps show where Dyne Therapeutics is stronger or weaker against peers. For peer comparison, Dyne Therapeutics has a market cap of 2.9 B, P/E of 35.58.
Unless otherwise specified, data for Dyne Therapeutics is compiled from periodic company reporting and market reference feeds and standardized for comparability. Analyst projections are included when active coverage applies. Updates may occur throughout the day.